

References

S-272

1. **Acute Myeloid Leukemia**
2. InterQual® Level of Care Criteria 2021, Acute Care Adult, McKesson Health Solutions, LLC
3. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis. *Haematol.* 2017;102(5):865–873.
4. Heidrich K, Thiede C, Schafer-Eckart K, et al. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. *Ann Oncol.* 2017;28(11):2793-2798.
5. Frazer J, Couban S, Doucette S, et al. Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. *Curr Oncol.* 2017;24(2):e123-e130.
6. Miyamoto T, Nagafuji K, Fujisaki T, et al. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. *Int J Hematol.* 2018;107(4):468-477.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Acute myeloid leukemia. Version 1.2022.
8. Blum WG, Mims AS. Treating acute myeloid leukemia in the modern era: A primer. *Cancer.* 2020;126(21):4668-4677.
9. Koenig K, Mims A, Levis MJ, Horowitz MM. The changing landscape of treatment in acute myeloid leukemia. *Am Soc Clin Oncol Educ Book.* 2020;40:1-12.
10. Dholaria B, Savani BN, Hamilton BK, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: An evidence-based review from the American Society of Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant.* 2021;27:6-20.
11. Kawashima N, Ishikawa Y, Atsuta Y, et al. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. *Cancer Science.* 2020;111(7):2472-2481.
12. Hu G-H, Cheng Y-F, Lu A-D, et al. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. *BMC Cancer.* 2020;20(1):553.

13. Hunter BD, Chen Y-B. Current Approaches to Transplantation for FLT3-ITD AML. *Current Hematol Malign Rep.* 2020;15(1):1-8.
14. Song Y, Yin Z, Ding J, Wu T. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation is a good choice for acute myeloid leukemia and myelodysplastic syndrome: A meta-analysis of randomized controlled trials. *Front Oncol.* 2021;11:708727.
15. Scott BL, Pasquini MC, Fei M, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial. *Transplant Cell Ther.* 2021;27(6):483.e1-483.e6.
16. Bejanyan N, Zhang M, Bo-Subait K, et al. Myeloablative conditioning for allogeneic transplantation results in superior disease-free survival for acute myelogenous leukemia and myelodysplastic syndromes with low/intermediate but not high disease risk index: A Center for International Blood and Marrow Transplant Research study. *Transplant Cell Ther.* 2021;27(1):68.e1-68.e9.
17. **Multiple Myeloma/POEMS Syndrome**
18. Garderet L, Cook G, Auner HW, et al. Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. *Leuk Lymphoma.* 2017;58(4):797-808.
19. Autore F, Innocenti I, Luigetti M, et al. Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. *Hematol Oncol.* 2018;36(2):392-398.
20. Cook G, Iacobelli S, van Biezen A, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. *Haematol.* 2017;102(1):160-167.
21. Maffini E, Storer BE, Sandmaier BM, et al. Long-term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. *Haematol.* 2019;104(2):380-391.
22. Ziogas DC, Terpos E, Dimopoulos MA. When to recommend a second autograft in patients with relapsed myeloma? *Leuk Lymphoma.* 2017;58(4):781-787.
23. Schneidawind C, Duerr-Stoerzer S, Faul C, et al. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation. *Clin Transplant.* 2017;31(7).
24. Marini C, Maia T, Bergantim R, et al. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. *Ann Hematol.* 2019;98(2):369-379.
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Multiple myeloma. Version 5.2022

26. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. *Blood Cancer J.* 2020;10(9):94.
27. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol.* 2020;95(5): 48-567.
28. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): A multicentre, randomised, open-label, phase 3 study. *Lancet Haematol.* 2020;7(6): e456-e468.
29. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. *N Engl J Med.* 2017;376(14):1311-1320.
30. Mian H, Mian OS, Rochweg B, et al. Autologous stem cell transplant in older patients (age greater than or equal to 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. *J Geriatr Oncol.* 2020;11(1):93-99.
31. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. *J Clin Oncol.* 2019;37(7):589-597.
32. Goldschmidt H, Baertsch MA, Schlenzka J, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: The randomized GMMG phase III trial ReLApSE. *Leukemia.* 2021;35(4):1134-1144.
33. Ikeda T, Mori K, Kawamura K, et al. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. *Hematol Oncol.* 2019;37(5):586-594.
34. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol.* 2019;37(14):1228-1263.
35. Morè S, Corvatta L, Manieri VM, et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? *Cells.* 2022;11(4):606.
36. Hernández-Rivas JÁ, Ríos-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing landscape of relapsed and/or refractory multiple myeloma (MM): Fundamentals and controversies. *Biomark Res.* 2022;10(1):1.
37. **Non-Hodgkin Lymphoma**
38. National Cancer Institute. Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version.

39. Picleanu A, Novella S, Monter A, Garcia-Cadenas I, et al. Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases. *Ann Hematol.* 2017;96:787-796.
40. Gilli S, Novak U, Taleghani M, Baerlocher G, et al. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. *Ann Hematol.* 2017;96:421-429.
41. Gupta A, Gokarn A, Rajamanickam D, Punatar S, Thippeswamy R, Mathew L, et al. Lomustine, cytarabine, cyclophosphamide, etoposide – An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. *J Cancer Res Ther.* 2018;14(5):926-933.
42. Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. *Blood.* 2018;132(3):245-253.
43. Bozkaya Y, Uncu D, Dağdaş S, et al. Evaluation of lymphoma patients receiving high-dose therapy and autologous stem cell transplantation: Experience of a single center. *Indian J Hematol Blood Transfus.* 2017;33(3):361-369.
44. Jiménez-Ubieto A, Grande C, Caballero D, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. *Hematol Oncol.* 2018;36(5):765-772.
45. Strüßmann T, Fritsch K, Baumgarten A, et al. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. *Br J Haematol.* 2017;178(6):927-935.
46. Casasnovas RO, Ysebaert L, Thieblemont C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. *Blood.* 2017;130(11):1315-1326.
47. Qualls D, Sullivan A, Li S, et al. High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-hodgkin lymphoma with synchronous central nervous system involvement. *Clin Lymphoma Myeloma Leuk.* 2017;17(12):884-888.
48. Fujita N, Kobayashi R, Atsuta Y, et al. Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. *Int J Hematol.* 2019;109(4):483-490.
49. García-Noblejas A, Cannata-Ortiz J, Conde E, et al. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). *Ann Hematol.* 2017;96(8):1323-1330.

50. Wang J, Wei L, Ye J, et al. Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. *Int J Hematol*. 2018;107(1):98-104.
51. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: B-cell lymphomas. v.2.2022.
52. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: T-cell lymphomas. v.2.2022.
53. Mamez AC, Dupont A, Blaise D, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: A retrospective study in 285 patients from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). *J Hematol Oncol*. 2020;13(1):56.
54. Ghosh N, Ahmed S, Ahn KW, et al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant. *JAMA Oncol*. 2020;6(7):1011-1018.
55. Shah NN, Ahn KW, Litovich C, et al. Allogeneic transplantation in elderly patients ≥ 65 years with non-Hodgkin lymphoma: a time-trend analysis. *Blood Cancer J*. 2019;9(12):97. Erratum in: *Blood Cancer J*. 2021;11(4):82.
56. Zoellner AK, Unterhalt M, Stilgenbauer S, et al. European Mantle Cell Lymphoma Network. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: A post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. *Lancet Haematol*. 2021;8(9):e648-e657.
57. Krüger, W. H., Hirt, C., Basara, N., et al (2021). Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). *Annals of hematology*, 100(6), 1569–1577.
58. Schmitz N, Truemper L, Bouabdallah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. *Blood*. 2021;137(19):2646-2656.
59. Du J, Yu D, Han X, Zhu L, Huang Z. comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: A systematic review and meta-analysis. *JAMA Netw Open*. 2021;4(5):e219807.
60. Munshi PN, Hamadani M, Kumar A, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. *Bone Marrow Transplant*. 2021;56(12):2911-2921.
61. **Hodgkin Lymphoma**
62. American Cancer Society. High-dose Chemotherapy and Stem Cell Transplant for Hodgkin Lymphoma. Updated May 1, 2018.

63. Adult Hodgkin Lymphoma Treatment (PDQ®)-Health Professional Version. 2017.
64. NCCN Clinical practice guidelines in oncology: Hodgkin lymphoma. Version 2.2022.
65. Hodgkin Lymphoma Stages. Accessed February 14, 2020.
66. Gao L, Xiang X, Zhang C, et al. Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: A multicenter retrospective cohort study. *Hematology*. 2019; 24(1):225-231.
67. Martínez C, Gayoso J, Canals C, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: A registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. *J Clin Oncol*. 2017; 35(30):3425-3432.
68. National Cancer Institute (NCI). Adult Hodgkin Lymphoma Treatment (PDQ) - Health Professional Version. Updated November 24, 2021.
69. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood*. 2018;132(25): 2639-2642.
70. Smith EP, Li H, Friedberg JW, et al. Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). *Biol Blood Marrow Transplant*. 2018;24(4):700-707.
71. Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. *Am J Hematol*. 2017;92(9):879-884.
72. Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2020;26(7):1247-1256.
73. Scordo M, Wang TP, Ahn KW, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. *JAMA Oncol*. 2021;7(7):993-1003.
74. **Chronic Myeloid Leukemia**
75. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Chronic myeloid leukemia. Version 3.2022.
76. Chhabra S, Ahn KW, Hu ZH, et al. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. *Blood Adv*. 2018;13;2(21):2922-2936.

77. Bewersdorf JP, Zeidan AM. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). *Cancers (Basel)*. 2021;13(7):1610.
78. **Acute Lymphoblastic Leukemia**
79. Santoro N, Ruggeri A, Labopin M, et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: A study on behalf of the Acute Leukemia Working Party of the EBMT. *J Hematol Oncol* [serial online]. 2017;10(1):113.
80. Giebel S, Labopin M, Nagler A, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematolog*. 2017;102(1):139-149.
81. Pavlu J, Labopin M, Zoellner AK, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. *Cancer*. 2017;123(11):1965-1970.
82. PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Acute Lymphoblastic Leukemia Treatment. Bethesda, MD: National Cancer Institute. Updated December 22, 2021
83. PDQ® Adult Treatment Editorial Board. PDQ Adult Acute Lymphoblastic Leukemia Treatment. Bethesda, MD: National Cancer Institute. Updated January 18, 2022.
84. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Acute lymphoblastic leukemia. Version 4.2021.
85. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Pediatric acute lymphoblastic leukemia. Version 1.2022.
86. Pui C-H, Rebora P, Schrappe M, et al. outcome of children with hypodiploid acute lymphoblastic leukemia: A retrospective multinational study. *J Clin Oncol*. 2019;37(10):770-779.
87. Chang J, Douer D, Aldoss I, et al. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia. *Cancer Med*. 2019;8(6):2832-2839.
88. DeFilipp Z, Advani AS, Bachanova V, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: Updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2019;25(11):2113-2123.

89. El Fakih R, Ahmed S, Alfraih F, Hanbali A. Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients. *Hematol Oncol Stem Cell Ther.* 2017;10(4):252-258.
90. Yaniv I, Krauss AC, Beohou E, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: A retrospective EBMT-PDWP study. *Biol Blood Marrow Transplant.* 2018;24(8):1629-1642.
91. Trujillo ÁM, Karduss AJ, Suarez G, et al. Haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source. *Transplant Cell Ther.* 2021;27(5):427.e1-427.e7.
92. Rosko A, Wang HL, de Lima M, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. *Am J Hematol.* 2017;92(1):42-49.
93. **Systemic Light Chain Amyloidosis**
94. D'Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. *Br J Haematol.* 2017; 176(5):728-742.
95. Afrough A, Saliba RM, Hamdi A, et al. Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2018; 24(11):2197-2203.
96. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Systemic Light Chain Amyloidosis. Version 1.2022.
97. Yeh JC, Shank BR, Milton DR, Qazilbash MH. Adverse prognostic factors for morbidity and mortality during peripheral blood stem cell mobilization in patients with light chain amyloidosis. *Biol Blood Marrow Transplant.* 2018; 24(4):815-819.
98. Nguyen VP, Landau H, Quillen K, et al. Modified high-dose melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis. *Biol Blood Marrow Transplant.* 2018;24(9):1823-1827.
99. Cai Y, Xu S, Li N, Li S, Xu G. Efficacy of chemotherapies and stem cell transplantation for systemic AL amyloidosis: A network meta-analysis. *Front Pharmacol.* 2020;10:1601.
100. Sharpley FA, Petrie A, Mahmood S, Sachchithanatham S, Lachmann HJ, Gillmore JD, et al. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. *Br J Haematol.* 2019;187(5):642-652.
101. Sharpley FA, Manwani R, Petrie A, et al. Autologous stem cell transplantation vs bortezomib based chemotherapy for the first-line treatment

of systemic light chain amyloidosis in the UK. *Eur J Haematol.* 2021;106(4):537-545.

102. **Waldenström Macroglobulinemia**
103. Cornell R. Allogeneic transplantation for relapsed Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. *Biol Blood Marrow Transplant.* 2017; 23:60-66.
104. Abeykoon J. New developments in the management of Waldenström macroglobulinemia. *Cancer Manag Res.* 2017; 9:73-83.
105. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncol.* 2017; 3(9):1257-1265
106. Talaulikar D, Tam CS, Joshua D, et al. Treatment of patients with Waldenström macroglobulinemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Intern Med J.* 2017; 47(1):35-49.
107. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma. Version 2.2022.
108. Gertz MA. Waldenström macroglobulinemia: 2019 Update on diagnosis, risk stratification, and management. *Am J Hematol.* 2019; 94(2):266-276.
109. Parrondo RD, Reljic T, Iqbal M, et al. Efficacy of autologous and allogeneic hematopoietic cell transplantation in Waldenström macroglobulinemia: A systematic review and meta-analysis. *Clin Lymphoma Myeloma Leuk.* 2020;20(10):e694-e711.
110. Cornell RF, Bachanova V, D'Souza A, et al. Allogeneic transplantation for relapsed Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. *Biol Blood Marrow Transplant.* 2017;23(1):60-66.
111. Ahmed S, Zhao Q, Hanel W, et al. Post-relapse survival in Waldenström macroglobulinemia patients experiencing therapy failure following autologous transplantation. *Hematol Oncol.* 2022;40(1):48-56.
112. **Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma**
113. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Chronic lymphocytic leukemia/Small lymphocytic lymphoma. V.2.2022.
114. Kharfan-Dabaja MA, Moukalled N, Reljic T, El-Asmar J, Kumar A. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. *Hematol Oncol Stem Cell Ther.* 2018;11(2):53-64.

115. Roeker LE, Dreger P, Brown JR, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. *Blood Adv.* 2020;4(16):3977-3989.
116. Kim HT, Shaughnessy CJ, Rai SC, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. *Blood Adv.* 2020;4(17):4113-4123.
117. Farina L, Barretta F, Scarfò L, et al. Refractory and 17p-deleted chronic lymphocytic leukemia: Improving survival with pathway inhibitors and allogeneic stem cell transplantation. *Biol Blood Marrow Transplant.* 2020;26(10):e256-e262.
118. Smolewski P, Robak T. Current treatment of refractory/relapsed chronic lymphocytic leukemia: A focus on novel drugs. *Acta Haematol.* 2021;144(4):365-379.
119. **Myelodysplastic Syndromes and Myeloproliferative Neoplasms**
120. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, Version 2.2022.
121. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 3.2022.
122. Heidenreich S, Ziagkos D, de Wreede LC, et al. Allogeneic stem cell transplantation for patients age ≥ 70 years with myelodysplastic syndrome: A retrospective study of the MDS subcommittee of the chronic malignancies working party of the EBMT. *Biol Blood Marrow Transplant.* 2017;23(1):44-52.
123. Beelen DW, Trensche R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): A randomised, non-inferiority, phase 3 trial. *Lancet Haematol.* 2020;7(1):e28-e39.
124. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. *J Clin Oncol.* 2017;35(11):1154-1161.
125. Kröger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase iii study of the EBMT (RICMAC Trial). *J Clin Oncol.* 2017;35(19):2157-2164.
126. Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. *Blood Adv.* 2020;4(9):1965-1973.
127. Chatain N, Koschmieder S, Jost E. Role of inflammatory factors during disease pathogenesis and stem cell transplantation in myeloproliferative neoplasms. *Cancers (Basel).* 2020;12(8):2250.

128. Danielson N, Byrne M. Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. *Curr Hematol Malig Rep.* 2020;15(4):268-275.
129. Prem S, Atenafu EG, Lam W, et al. Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival. *Eur J Haematol.* 2020;104(2):116-124.
130. Bewersdorf JP, Sheth AH, Vetsa S, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis-A systematic review and meta-analysis. *Transplant Cell Ther.* 2021;27(10):873.e1-873.e13.
131. **Donor Leukocyte Infusion**
132. Vaezi M, Zokaasadi M, Shahsavari Pour S, et al. The role of donor leukocyte infusions in the treatment of relapsed acute leukemia after allogeneic stem cell transplantation: A retrospective analysis. *Int J Hematol-Oncol Stem Cell Res.* 2018;12(3):184-191.
133. Miyamoto T, Fukada T, Nakashima M, et al. Donor leukocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program. *Biol Blood Marrow Transplant.* 2017;23:938-944.
134. Aladag E, Goker H, Buyukasik Y, Demiroglu H. Effect of salvage chemotherapy before donor lymphocyte infusion in patients with relapse after allogeneic hematologic stem cell transplantation. *Transplant Proc.* 2021;53(1):391-395.
135. Ali T, Behfar M, Mohseni R, Salajegheh P, et al. Escalated dose donor lymphocyte infusion treatment in patients with primary immune deficiencies after HSCT with reduced-intensity conditioning regimen. *Hematol Oncol Stem Cell Ther.* 2021:S1658-3876(21)00059-5.
136. Dholaria B, Savani BN, Labopin M, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. *Haematologica.* 2020;105(1):47-58.
137. Krakow EF. Current state of non-engrafting donor leukocyte infusion (focus on microtransplantation for acute myeloid leukemia). *Curr Opin Hematol.* 2019;26(6):373-378.